Seltorexant
Small molecule
Also known as MIN-202, JNJ-42847922
Evidence outlook · lead readout
NCT04533529 · Depressive Disorder, Major
The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
NCT04533529: The initial treatment phase randomized 588 participants to seltorexant or matching placebo and kept participants and investigators blinded; among the prespecified efficacy population, the primary MADRS depression-score endpoint was significantly better with seltorexant at Day 43 (p=0.007). The subsequent one-year open-label phase continued participants from this randomized study and provides less controlled long-term safety information.
Also in development:Alzheimer's Disease · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04513912 NCT04513912 · Depressive Disorder, Major The study randomly assigned 757 participants to double-blind seltorexant or active-comparator quetiapine XR treatment. Its primary endpoint was clinical—the proportion with at least a 50% improvement in MADRS score at Week 26. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT04513912 | 3 | Percentage of Participants with Response (>=50 Percent improvement in MADRS total score from baseline) at Week 26 2023-10-03 | Response (>=50% MADRS improvement) at week 26: 57.4% seltorexant vs 53.4% quetiapine XR; did not reach statistical significance | Partial signal | link ↗ |
View 2 more trials
NCT06559306 NCT06559306 · Depressive Disorder, Major Registry: NCT06559306 | 3 | Part 1: Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Day 43 (Baseline, Day 43); Part 2: Time from Randomization to the First Relapse in Participants Who Achieve a Stable Response (Time from randomization to the first Relapse during the maintenance phase (up to 2 years and 10 months)) 2026-12-30 | In progress: results expected 30 Dec 2026 | not yet graded | link ↗ |
NCT04533529 NCT04533529 · Depressive Disorder, Major The initial treatment phase randomized 588 participants to seltorexant or matching placebo and kept participants and investigators blinded; among the prespecified efficacy population, the primary MADRS depression-score endpoint was significantly better with seltorexant at Day 43 (p=0.007). The subsequent one-year open-label phase continued participants from this randomized study and provides less controlled long-term safety information. Registry: NCT04533529 | 3 | Double Blind (DB) Treatment Phase: Change From Baseline to Day 43 in Montgomery- Asberg Depression Rating Scale (MADRS) Total Score- Estimand 1 (Baseline (Day 1), Day 43); Open Label (OL) Treatment Phase: Number of Participants With Treatment Emergent Adverse Events (TEAEs) (From start of the treatment in OL phase (OL Day 1 [Day 43 from study baseline]) up to 2 days after last dose in OL phase (up to 52.28 weeks)); OL Treatment Phase: Number of Participants With Treatment-Emergent Adverse Events of Special Interest (AESI) (From start of the treatment in OL phase (OL Day 1 [Day 43 from study baseline]) up to 2 days after last dose in OL phase (up to 52.28 weeks)); OL Treatment Phase: Change From Baseline in Vital Signs: Blood Pressure (OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52); OL Treatment Phase: Change From Baseline: Body Mass Index (BMI) (OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52); OL Treatment Phase: Change From Baseline in Vital Signs: Temperature (OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52); OL Treatment Phase: Change From Baseline in Vital Signs: Pulse Rate (OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52); OL Treatment Phase: Change From Baseline in Weight (OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52); OL Treatment Phase: Change From Baseline in Waist Circumference (OL Baseline (OL Day 1 [Day 43 from study baseline]) and Week 52); OL Treatment Phase: Number of Participants With Shift From Baseline in Suicidal Ideation and Behavior Using the Columbia Suicide Severity Rating Scale (C-SSRS) (From DB Baseline (Day 1) up to Week 52); OL Follow Up Phase: Physician Withdrawal Checklist (PWC-20) Total Scores at Start of OL Follow Up (Start of OL Follow Up (Week 52)); OL Follow Up Phase: Physician Withdrawal Checklist (PWC-20) Total Scores at Follow up Visit 1 (Follow up Visit 1: 1 day after end of OL phase (Week 52.14)); OL Follow Up Phase: Physician Withdrawal Checklist (PWC-20) Total Scores at Follow up Visit 2 (Follow Up Visit 2: 2 weeks after end of OL phase (Week 54)); OL Treatment Phase: Number of Participants With Electrocardiogram (ECG) Abnormalities (Week 52); OL Treatment Phase: Number of Participants With Clinically Significant Laboratory Abnormalities (From DB Baseline (Day 1) to Week 52); OL Treatment Phase: Number of Participants With Sexual Dysfunction as Determined by Arizona Sexual Experiences Scale (ASEX) Score (Week 52) 2023-04-25 | Double Blind (DB) Treatment Phase: Change From Baseline to Day 43 in Montgomery- Asberg Depression Rating Scale (MADRS) Total Score- Estimand 1 (Baseline (Day 1), Day 43): DB Treatment Phase: Seltorexant 20 mg -12.9 Units on a scale (Standard Deviation 9.63) vs Double Blind (DB) Treatment Phase: Placebo -10.5 Units on a scale (Standard Deviation 10.26) | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (24)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Alzheimer's Disease: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Seltorexant: this drug | Phase 2 | Small molecule | Orexin-2 receptor (OX2R) | not yet graded | No reviewed efficacy summary in this indication | |
| Benzgalantamine (Zunveyl) | Approved | Small molecule | Acetylcholinesterase/nicotinic receptor (prodrug) | not yet graded | No reviewed efficacy summary in this indication | |
| Donanemab (Kisunla) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | Partial signal | NCT05108922: Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 Positron Emission Tomography (PET) Scan (Superiority) on Donanemab Versus Aducanumab (6 Months): Donanemab 37.9% (95% CI 26.2 to 49.6) vs Aducanumab 1.6% (95% CI 0 to 4.6) | |
| Donepezil (Aricept) | Approved | Small molecule | Acetylcholinesterase | Partial signal | NCT00630851: Primary endpoint, SIB change at 6 months: mean difference 5.9 points vs placebo, statistically significant (ARICEPT label, Swedish 6-month study, 248 randomized). | |
| Lecanemab (Leqembi) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | Partial signal | NCT01767311: ADCOMS change from baseline at Month 12 (lower = less decline): lecanemab 10 mg/kg biweekly 0.077 and 10 mg/kg monthly 0.084 vs placebo 0.113; lower doses did not separate: 2.5 mg/kg biweekly 0.134, 5 mg/kg monthly 0.119, 5 mg/kg biweekly 0.116. missed | |
| AR1001 | Phase 3 | Small molecule | PDE5 | Partial signal | NCT03625622: Primary (ADAS-Cog-13 at Week 26): no significant differences between treatment groups in the overall population; post-hoc monotherapy subgroup on AR1001 30 mg improved 4.019 points (p=0.012). missed | |
| Bezisterim | Phase 3 | Small molecule | ERK/NF-kB inflammatory | Partial signal | No reviewed efficacy summary in this indication | |
| Brexpiprazole (Rexulti) | Phase 3 | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | Partial signal | NCT01862640: Change in CMAI Total score from baseline to Week 12 vs placebo (Study 1 = NCT01862640): brexpiprazole 2mg/day adjusted mean difference -3.77 (95% CI -7.38 to -0.17), p=0.040; brexpiprazole 1mg/day 0.23 (95% CI -3.40 to 3.86), p=0.90 NCT03620981: Change From Baseline in Cohen-Manfield Agitation Inventory(CMAI) Score at 10 Weeks After Dosing. (Baseline and 10 weeks first dose, on average 10 weeks): Brexpiprazole 1 mg -11.7 units on a scale (Standard Error 1.2) | Brexpiprazole 2 mg -15.2 units on a scale (Standard Error 1.05) vs Placebo -8 units on a scale (Standard Error 1.03) | |
| Buntanetap | Phase 3 | Small molecule | APP/tau/alpha-synuclein/TDP-43 (translation) | Partial signal | NCT05686044: ADAS-Cog11 change at Week 12: -2.32 placebo vs -1.34 (7.5 mg), -3.01 (15 mg), and -2.24 (30 mg) buntanetap/Posiphen; ADCS-CGIC at Week 12: 3.58 placebo vs 3.96 (7.5 mg), 3.61 (15 mg), and 3.83 (30 mg). | |
| Hydromethylthionine Mesylate | Phase 3 | Small molecule | Tau aggregation; Acetylcholine | Partial signal | NCT03446001: Change From Baseline on Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog11) (16 mg/Day vs Control) (52 weeks): TRx0237 16 mg/Day 1.34 score on a scale (95% CI 0.32 to 2.36) vs Control 1.71 score on a scale (95% CI 0.69 to 2.73) NCT01689233: As-randomized primary comparison (100 mg vs 4 mg twice daily, the trial's pre-specified design): no significant difference on primary or secondary outcomes. Post-hoc modified-primary-outcome monotherapy cohort analysis: ADAS-cog effect size -3.14 (95% CI -5.32 to -0.97, p=0.0047) for 100 mg monotherapy (n=76) vs 4 mg as-randomized (n=388); -4.22 (95% CI -6.19 to -2.24, p<0.0001) for 4 mg monotherapy (n=79) vs 4 mg add-on (n=309) | |
| Masitinib | Phase 3 | Small molecule | KIT (c-Kit), also PDGFR and Lyn/Fyn kinases | Partial signal | NCT01872598: Co-primary endpoints at week 24, masitinib 4.5 mg/kg/day vs placebo, each tested at 2.5%: ADAS-cog difference -2.15 (97.5% CI -3.48 to -0.81), p<0.001 (met); ADCS-ADL difference +1.82 (97.5% CI -0.15 to 3.79), p=0.038 (not met at the 2.5% level) | |
| Masupirdine | Phase 3 | Small molecule | Serotonin 5-HT6 receptor | Partial signal | NCT02580305: ADAS-Cog 11 change from baseline at Week 26: placebo +2.6 (SE 0.5); masupirdine 50 mg +2.0 (SE 0.5), difference vs placebo -0.5 (95% CI -1.8, 0.7; P=.41); masupirdine 100 mg +2.5 (SE 0.5), difference vs placebo -0.1 (95% CI -1.4, 1.2; P=.90) missed | |
| MLC901 (NeuroAiD II) | Phase 3 | Botanical | Traditional Chinese medicine (multi-component) | not yet graded | No reviewed efficacy summary in this indication | |
| Remlifanserin | Phase 3 | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Remternetug | Phase 3 | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | Partial signal | No reviewed efficacy summary in this indication | |
| Sodium Oligomannate | Phase 3 | Small molecule | Gut microbiome / neuroinflammation | Reliable signal | NCT02293915: Change in ADAS-cog12 from baseline to Week 36 (GV-971 minus placebo): -2.15 points (95% CI -3.07 to -1.23; p<0.0001; Cohen's d 0.53), favoring GV-971 | |
| Tertomotide | Phase 3 | Peptide | Telomerase (hTERT) | Partial signal | NCT05189210: 52주 차 ADAS-cog11의 최소제곱평균값 변화량은 GV1001 0.56mg과 1.12mg 투약군에서 각각 4.14점, 4.31점으로 위약군 4.30점 (LS-mean change in ADAS-cog11 at week 52: GV1001 0.56 mg 4.14 points, 1.12 mg 4.31 points, placebo 4.30 points; not statistically significant) missed | |
| Tricaprilin | Phase 3 | Small molecule | Ketone-body metabolism | Partial signal | NCT01741194: Change from baseline at 26 weeks, ADAS-Cog11 (APOE4 non-carriers): placebo (n=138) 0.0 vs AC-1204/tricaprilin (n=137) 0.6; LS mean difference -0.761, p=0.2458 (not significant) missed | |
| Trontinemab | Phase 3 | Multispecific antibody | Amyloid-beta (monoclonal antibody) | not yet graded | No reviewed efficacy summary in this indication | |
| Xanomeline / Trospium Chloride (Cobenfy) | Phase 3 | Small molecule | Muscarinic M1/M4 receptor (agonist/antagonist combination) | not yet graded | No reviewed efficacy summary in this indication | |
| AGB101 | Phase 2/3 | Small molecule | Synaptic vesicle glycoprotein 2A (SV2A), low-dose | Partial signal | NCT03486938: CDR-SB difference vs placebo -0.10 (95% CI -0.85 to 0.58), not significant missed | |
| Blarcamesine | Phase 2/3 | Small molecule | Sigma-1 receptor / muscarinic receptor (dual) | Partial signal | NCT03790709: Co-primary endpoints at 48 weeks: ADAS-Cog13 difference vs placebo -2.027 (95% CI -3.522 to -0.533; P = 0.008); ADCS-ADL difference 0.775 (95% CI -0.874 to 2.423; P = 0.357, not significant). missed | |
| Deramciclane | Phase 2/3 | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Deraphan | Phase 2/3 | Small molecule | NMDA receptor / 5-HT2A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Emestedastat (Xanamem) | Phase 2/3 | Small molecule | 11-beta-HSD1 | Partial signal | NCT02727699: ADAS-Cog v14 (Baseline, Week 12): Xanamem™ -1.5 units on a scale (Standard Deviation 6.47) vs Placebo -0.7 units on a scale (Standard Deviation 6.65) | |
| Etalanetug | Phase 2/3 | Monoclonal antibody | Tau (monoclonal antibody) | Weak signal | Featured results are safety only in this race | |
| Nivegacetor | Phase 2/3 | Undisclosed | Gamma-secretase (modulator) | not yet graded | No reviewed efficacy summary in this indication | |
| PM012 | Phase 2/3 | Botanical | Traditional Chinese medicine (multi-component) | Partial signal | No reviewed efficacy summary in this indication | |
| T3D-959 | Phase 2/3 | Small molecule | PPAR delta/gamma | Partial signal | No reviewed efficacy summary in this indication | |
| 50561 | Phase 2 | Small molecule | RAC1 | Partial signal | No reviewed efficacy summary in this indication | |
| AADvac1 | Phase 2 | Vaccine | Tau | Weak signal | Featured results are safety only in this race | |
| ABvac40 | Phase 2 | Vaccine | Amyloid-beta (Aβx-40) | Partial signal | Featured results are non-efficacy and safety only in this race | |
| ACI-35.030 | Phase 2 | Vaccine | Tau | Partial signal | Featured results are safety only in this race | |
| AD04 | Phase 2 | Vaccine | Aluminium hydroxide (Alhydrogel) | not yet graded | No reviewed efficacy summary in this indication | |
| AstroStem | Phase 2 | Cell therapy | Mesenchymal stem cell therapy | Weak signal | NCT03117738: ADAS-Cog change at Week 30: 5.9 (SD 6.8) AstroStem vs 3.0 (SD 5.4) placebo; n=7 vs 7. | |
| AV-1959R | Phase 2 | Vaccine | Amyloid-beta | Weak signal | Featured results are safety only in this race | |
| Bepranemab | Phase 2 | Monoclonal antibody | Tau (monoclonal antibody) | Partial signal | NCT04867616: Primary endpoint, change in CDR-SB total score at Week 80: no benefit of low- or high-dose bepranemab over placebo in the overall study population (per UCB; no figures or p-value released). Key secondary outcomes favoured bepranemab: tau accumulation slowed by 33% to 58% and ADAS-Cog14 decline by 21% to 25% vs placebo. missed | |
| Betovumeline / Fesoterodine (ML-007C-MA) | Phase 2 | Small molecule | Muscarinic M1 and M4 receptors (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| BEY2153 | Phase 2 | Small molecule | APP/tau (translation) | Partial signal | No reviewed efficacy summary in this indication | |
| Cerebrolysin | Phase 2 | Peptide | Porcine brain-derived neuropeptide mixture (multi-target) | Partial signal | NCT00911807: Week 28 ADAS-COG+ change: -2.348 Cerebrolysin + donepezil, -1.711 Cerebrolysin, and -1.246 donepezil; overall p=0.6348. Cerebrolysin + donepezil vs donepezil: mean difference -1.080 (95% CI -3.324 to 1.163; p=0.3434). missed | |
| Deulumateperone | Phase 2 | Small molecule | Serotonin 5-HT2A / dopamine D1-D2 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Diranersen | Phase 2 | RNA / oligonucleotide | MAPT mRNA (RNAi/ASO) | Weak signal | NCT05399888: Diranersen/BIIB080 (NCT05399888), Phase 2 CELIA study: primary endpoint (dose-response on CDR-SB change from baseline at Week 76) not met. missed | |
| Edaravone (TTYP01) | Phase 2 | Small molecule | oxidative stress | not yet graded | No reviewed efficacy summary in this indication | |
| Enrupatinib | Phase 2 | Small molecule | CSF-1R | not yet graded | No reviewed efficacy summary in this indication | |
| HT-4253 | Phase 2 | Small molecule | LRRK2 | not yet graded | No reviewed efficacy summary in this indication | |
| Laromestrocel (Lomecel-B) | Phase 2 | Cell therapy | Mesenchymal stem cell therapy | Weak signal | Featured results are safety only in this race | |
| Lemborexant (Dayvigo) | Phase 2 | Small molecule | Orexin receptor (repositioned) | Partial signal | NCT03001557: 4-week actigraphy endpoints vs placebo: L5 (restlessness measure) significantly decreased at 2.5mg, 5mg and 15mg doses (all p<0.05); relative amplitude significantly improved at 5mg and 15mg (both p<0.05); mean duration of sleep bouts significantly improved at 5mg (p<0.01) and 15mg (p=0.002). | |
| Leronlimab | Phase 2 | Monoclonal antibody | CCR5 co-receptor | not yet graded | No reviewed efficacy summary in this indication | |
| LHP588 | Phase 2 | Small molecule | Gingipain | not yet graded | No reviewed efficacy summary in this indication | |
| Lifonebart (VHB937) | Phase 2 | Monoclonal antibody | TREM2 | not yet graded | No reviewed efficacy summary in this indication | |
| Mivelsiran | Phase 2 | RNA / oligonucleotide | APP mRNA (RNAi) | not yet graded | No reviewed efficacy summary in this indication | |
| MK-2214 | Phase 2 | Monoclonal antibody | Phospho-tau (pSer413) | Partial signal | Featured results are safety only in this race | |
| Moponetug | Phase 2 | Monoclonal antibody | Tau (monoclonal antibody) | not yet graded | No reviewed efficacy summary in this indication | |
| NTRX-07 | Phase 2 | Small molecule | CB2 receptor | Weak signal | Featured results are safety only in this race | |
| ONO-2020 | Phase 2 | Small molecule | Epigenetic regulation (target undisclosed) | not yet graded | No reviewed efficacy summary in this indication | |
| Pegipanermin | Phase 2 | Biologic (subtype unspecified) | Soluble TNF (selective) | Partial signal | NCT05318976: Change in Early and Mild Alzheimer's Cognitive Composite (EMACC) (24 Weeks): 1.0 mg/kg XPro1595 0.05 z-score (Standard Error 0.04) vs 1.0 mg/kg Placebo 0.07 z-score (Standard Error 0.05) missed | |
| PRI-002 | Phase 2 | Small molecule | Amyloid-beta-42 oligomerization | Partial signal | No reviewed efficacy summary in this indication | |
| RB-ADSC | Phase 2 | Cell therapy | Mesenchymal stem cell therapy | not yet graded | No reviewed efficacy summary in this indication | |
| RO7269162 | Phase 2 | Small molecule | Gamma-secretase | not yet graded | No reviewed efficacy summary in this indication | |
| SAR448851 | Phase 2 | Small molecule | TREM2 | Weak signal | Featured results are safety only in this race | |
| SHR-1707 | Phase 2 | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | Partial signal | No reviewed efficacy summary in this indication |
Large race: only the 60 furthest-along competitors are listed; 62 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Seltorexant to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.